SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Kendle International Inc. (KNDL)

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Jeff Mulder who wrote (7)2/19/1998 10:43:00 AM
From: Alan M. Solinger  Read Replies (1) of 53
 
Thanks for your last two notes. This area is growing very rapidly. There has also been a significant amount of consolidation in the industry. This includes Kendle. The industry will continue to need this kind of contract work-force. My "thing" is that having been in the arena for the last 20+ years as an investigator and as an insider (inside the pharma/biotech segment) for the last 7 years, I believe there needs to be more attention to detail by both the CROs and the "sponsors" -- the biotechs etc. Biotechnology is growing by leaps and bounds and will need an expanded workforce by in a way that will be utilizing staffing in spurts. Therefore, CROs and independent contractors will be vital. If the CROs are to survive, they need to be more ethical and pay more attention to detail and not to the bottom line -- Money.

There are several very large conglomerates in the industry which have a corner on the market with access to several of the major pharmaceutical companies. But they could be the ones to turn the industry around before too much damage is done. Hopefully, Kendle can become one of these leaders. However, they have not convinced me that they have the leadership scientifically to do this yet. Good luck to you. Alan
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext